MwanzoHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Bei iliyotangulia
€ 25.85
Bei za siku
€ 25.67 - € 25.67
Bei za mwaka
€ 19.52 - € 36.69
Thamani ya kampuni katika soko
3.58B USD
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 126.19M | 28.63% |
Mapato halisi | -125.30M | -357.42% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -1.02 | -326.67% |
EBITDA | -121.67M | -339.34% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
(USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 520.91M | 8.30% |
Jumla ya mali | 955.15M | 7.16% |
Jumla ya dhima | 459.74M | 7.87% |
Jumla ya hisa | 495.40M | — |
hisa zilizosalia | 124.20M | — |
Uwiano wa bei na thamani | 6.63 | — |
Faida inayotokana na mali | -39.90% | — |
Faida inayotokana mtaji | -43.18% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
(USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato halisi | -125.30M | -357.42% |
Pesa kutokana na shughuli | -92.38M | -191.68% |
Pesa kutokana na uwekezaji | -268.94M | -645.70% |
Pesa kutokana na ufadhili | 430.78M | 82,741.73% |
Mabadiliko halisi ya pesa taslimu | 69.49M | 203.27% |
Mtiririko huru wa pesa | -91.82M | -262.49% |
Kuhusu
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1 Jan 2004
Makao Makuu
Tovuti
Wafanyakazi
525